Abstract:1605 Objectives: Immunoglobulin (Ig) heavy chain framework region (FR) of V1 family has been verified to be a major determinant of malignant phenotype of V1 family B-cell lymphoma. The aim of this study was to investigate the possibility of using radioiodine labeled FR antisense oligonucleotides (ASONs) as an imaging agent or antisense therapeutic radiopharmaceutical in lymphoma. Methods: A 18-mer partial phosphorothioate oligonucleotide sequence was synthesized and grafted in 5′with a tyramine group which was further radio iodinated. Radio iodination of the tyramine derivatized oligonucleotides was performed using the chloramine T method.1)Normal CD-1 mice were injected via a tail vein with 148 kBq 125I-FR-ASON (2~3μg). Animals were sacrificed at 1, 2, 4 and 24 h and tissue samples were studied.2)Liposome-mediated 3.33 MBq 131I-FR-ASON(7 ~9 μg)were injected intratumorally tumor-bearing BALB/c mice (6 weeks after inoculation of 107 Namalwa cells) meanwhile liposome-mediated 131I labeled sense oligonucleotides serving as controls. Biodistribution was monitored by sequential scintigraphy and organ radioactivity measurement at 24 h after injection. Percentage of the injected dose per gram (%ID/g) of tumor and tumor/ non-tumor tissue ratios (T/NT) were calculated for each group of mice and the difference between two groups was assessed. Results: The 5′tyramine group allowed specific and stable radio labeling of the ASON with radioiodine. The radioactivity reached its peak at 1 h after injection, and then decreased rapidly in normal mice after intravenous administration of 125I-FR-ASON.The liver, stomach and intestine played an important role in biodistribution and radioactivity counts were low in bone, brain and blood. When 131I-FR-ASON injected intratumorally into mice grafted with Namalwa cell line, images showed tracer accumulate in tumor. Immediately after intratumoral administration, only tumor was visible. Scintiscans performed at 1 and 2 h showed elimination of the tracer from the tumor to the abdomen and at 24 h tumor was clearly seen. %ID/g of tumor and T/NT ratios for the sense group (control) were significantly lower (P Conclusions: Radio labeled Ig FR ASON showed high specificity in V1 family B-cell lymphoma, and it should be considered further for nuclear medicine imaging application and radionuclide antisense therapy.

[Preparation and Biodistribution of VIP-125I-ASON].

Pre-clinical Study on Tumor Vasoactive Intestinal Peptide Receptor Scintigraphy.

Studies of 99tcm Labeled Vasoactive Intestinal Peptide Ramification and Its Function

F-18 Labeled Vasoactive Intestinal Peptide Analogue in the PET Imaging of Colon Carcinoma in Nude Mice

Study on Biodistribution and Imaging of Radioiodinated Antisense Oligonucleotides in Nude Mice Bearing Human Lymphoma

Preparation and bioevaluation of 111 In-DTPA-avastin for non-invasive tumor targeted imaging

Biodistribution and γ Imaging of ~(125)I-labeled Goat Anti-human IgG Polyclonal Antibody in Nude Mice Bearing Human Colon Cancer Xenografts

Synthesis and single photon emission computed tomography imaging evaluation with 99mTc-labeled bevacizumab in colorectal cancer xenografts

Astatine-211 labelled a small molecule peptide: specific cell killing in vitro and targeted therapy in a nude-mouse model

Pharmacokinetics of 3-[125I]iodo-alpha-methyl-L-tyrosine, a tumor imaging agent, after probenecid loading in mice implanted with colon cancer DLD-1 cells

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation.

Preparation, biological characterization and preliminary human imaging studies of 68Ga-DOTA-IBA

Synthesis and Evaluation Of111in-Dota-mab109 Monoclonal Antibody for Potential SPECT Molecular Imaging

Synthesis and Radiolabeling of (111)In-Core-cross Linked Polymeric Micelle-Octreotide for Near-Infrared Fluoroscopy and Single Photon Emission Computed Tomography Imaging.

Biodistribution and anti-tumor efficacy of intratumorally injected necrosis-avid theranostic agent radioiodinated hypericin in rodent tumor models

Radioiodination, Purification, and Evaluation of Antihuman Tumor-Derived Immunoglobulin G Light Chain Monoclonal Antibody in Tumor-Bearing Nude Mice.

131)I Labeling and Bioactivity Evaluation of a Novel RGD Dimer Targeted to Integrin Αvβ3 Receptor

Development and evaluation of albumin binder-conjugated heterodimeric radiopharmaceuticals targeting integrin αvβ3 and CD13 for cancer therapy

Synthesis, Preclinical Toxicity, and Biodistribution of [18F]AVT-011 to Assess the P-Glycoprotein Function

[Use of 99Mtc-Survivin Antisense Oligonucleotide in Diagnosis of Hepatocellular Carcinoma: an Experiment with Mice].

Radiolabeled B9958 Derivatives for Imaging Bradykinin B1 Receptor Expression with Positron Emission Tomography: Effect of the Radiolabel-Chelator Complex on Biodistribution and Tumor Uptake